Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab Extension in ApoE4 Non-Carrier Alzheimer's Disease
NCT00996918Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2009
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Pfizer. Started Dec 2009; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00996918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996918.